About 1 500 reports

  • Interventional oncology market in Americas
  • Interventional oncology market in EMEA

About Interventional Oncology Interventional oncology procedures involve the diagnosis and treatment of cancer and cancer-related problems by using minimally invasive (MI) procedures performed under image guidance. Interventional oncology uses X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to...

  • Oncology
  • World
  • Boston Scientific Corporation
  • Medtronic, Inc.
  • Terumo Corporation
  • Oncology Drugs Market Characteristics
  • Oncology Drugs Market Segmentation

Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the...

  • Oncology
  • World
  • Company Financials
  • Gilead Sciences, Inc.
  • Novartis AG

Oncology Drugs Global Market Report 2018 ##.

  • Cancer
  • Oncology
  • Pathology
  • World

Chapter ## provides an introduction to the report.

  • Cancer
  • Oncology
  • Therapy
  • World
  • Demand
  • Global oncology biosimilars segmentation by application
  • Oncology biosimilars market in China: SWOT analysis

About Oncology Biosimilars Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting....

  • Oncology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.

Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025 Table ## Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025 Table ## Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2015–2025 Tab

  • Biosimilar
  • Oncology
  • APAC
  • World
  • Market Size

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-##, PD-L##, CTLA-##]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022 ##.

  • Oncology
  • Therapy
  • World
  • Market Size
  • ONCOLOGY, GLOBAL, PIPELINE FOR ONCOLOGY BY MOLECULAR TARGET, 2017
  • ONCOLOGY, GLOBAL, PIPELINE FOR KEY ONCOLOGY INDICATIONS BY MOLECULAR TARGET, 2017

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Summary Oncology comprises a large and diverse group of indications, encompassing virtually all sites and tissues in the human body. The diseases are characterized by abnormal cell proliferation,...

  • Oncology
  • World
  • Celgene Corporation
  • Novartis AG
  • Pfizer Inc.
  • 2 Supportive Care Oncology: Executive Summary
  • 3.4 EPIDEMIOLOGICAL FORECAST FOR SUPPORTIVE CARE IN ONCOLOGY (2016-2026)

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026 Summary Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation in any part of the body that may spread beyond the cells’ normal boundaries (WHO, 2017). Worldwide, it is estimated that...

  • Blood Disease
  • Oncology
  • United States
  • World
  • Forecast

Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023 ## Preface ## Scope and Methodology ##. ## Objectives of the study ##. ## Stakeholders ##. ## Data Sources ##. ##. ## Primary Sources ##. ##. ## Secondary Sources ##. ## Market Estimation ##. ##. ## Bo

  • Generic Drug
  • Oncology
  • Therapy
  • World
  • Market Size

##.

  • Oncology
  • Therapy
  • World
  • Market Size
  • SUPPORTIVE ONCOLOGY
  • 5.3 EPIDEMIOLOGY FOR SUPPORTIVE CARE IN ONCOLOGY (2016-2026)

PharmaFocus: Supportive Care in Oncology Summary Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced...

  • Oncology
  • United States
  • Amgen Inc.
  • BeyondSpring Pharmaceuticals Inc.
  • Helsinn Group
  • JNJ
  • 11 Aug 2014

CDT during the " Plenary Session: Including the Science of Oncology Award and Lecture" at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

  • Oncology
  • United States
  • Demand
  • Genmab group
  • Janssen Biotech, Inc.

PD-## ##. ##. ##. ##.

  • Oncology
  • Therapy
  • World
  • Market Size
  • BASIC INFORMATION

Kadcyla | ado-trastuzumab Oncology drug report: 2013-2015 analysis, 2016-2021 expectations emtansine December 2016 Armed antibody Kadcyla | ado-trastuzumab emtansine 2013-2015 analysis; 2016-2021 expectations Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Chemotherapy
  • Oncology
  • Therapy
  • North America
  • United States
  • DDAC=DOSE-DENSE DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; FEC = FLUOROURACIL, EPIRUBICIN, AND CYCLOPHOSPHAMIDE
  • ONGOING TRIALS OF PERJETA

Perjeta|pertuzumab Oncology drug report: 2012-2015 analysis, 2016-2021 expectations December 2016 In the spotlight Perjeta | pertuzumab 2012-2015 analysis; 2016-2021 expectations Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • Demand
  • Roche Group

Baynes, MD, PhD, Senior Vice President, Oncology and Inflammation Therapeutics at Gilead.

  • Leukemia
  • Oncology
  • United States
  • Gilead Sciences, Inc.
  • Roche Group
  • Ariad announces final decision from European Commission endorsing Iclusig's approved indications through-
  • BASIC INFORMATION

Iclusig|ponatinib Oncology drug report: 2013-2015 analysis, 2016-2021 expectations December 2016 Iclusig | ponatinib 2013-2015 analysis; 2016-2021 expectations Caught up in controversies Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • ARIAD Pharmaceuticals, Inc.
  • Incyte Corporation

Iressa | gefitinib Oncology drug report: 2002-2015 analysis, 2016-2021 expectations December 2016 Iressa | gefitinib 2006-2015 analysis; 2016-2021 expectations On a downward spiral Oncology Drug Report ANALYST Cancer Therapy Research Team Vikas.

  • Oncology
  • United States
  • Demand
  • AstraZeneca PLC
  • Roche Group
  • NEWS AROUND HERCEPTIN
  • 2 Sep 2013

Oncology drug report: Her ceptin |tr astuzum ab 2006-2015 analysis, 2016-2021 expectations November 2016 Herceptin | trastuzumab 2006-2015 analysis; 2016-2021 expectations Steady decline seen ahead Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • Biocon Limited
  • Roche Group
  • NEWS AROUND BLINCYTO
  • 01 Sept 16

Stein, M. D., clinical professor, Hematology/ Oncology at City of Hope.

  • Oncology
  • Therapy
  • United States
  • Demand
  • Amgen Inc.
  • CUMULATIVE SALES IN USD MN
  • Historical cumulative sales (2002 to 2015)

TS-## (tegafur, gimeracil, oteracil) ##.

  • Oncology
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • SALES MIX - US AND CANADA/INTERNATIONAL
  • Takeda announces the new drug application approval of Adcetris (brentuximab vedotin) in Japan for the treatment of malignant lymphoma

Oncology drug report: Adcet ris |brentu xima b ved oti n 2011-2015 analysis, 2016-2021 expectations November 2016 Adcetris| brentuximab vedotin 2011-2015 analysis; 2016-2021 expectations Orphan drug growing steadily Oncology Drug Report Analyst Cancer Therapy Research Team Vikas.

  • Oncology
  • North America
  • United States
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Royalty-related information
  • COMPANY PRESS RELEASES RELATED TO XALKORI

It is one of the major contributors to oncology revenue of Pfizer in recent years and is the third-largest oncology drug for the company.

  • Oncology
  • United States
  • AstraZeneca PLC
  • Pfizer Inc.
  • Roche Group
  • BASIC INFORMATION

NATIONAL ONCOLOGY COOPERATIVE GROUP.

  • Oncology
  • Targeted Therapy
  • United States
  • Demand
  • Celgene Corporation

(USA) ##.

  • Cancer
  • Oncology
  • United States
  • World
  • Market Shares
  • CURRENT AND FUTURE DIRECTIONS IN THE ONCOLOGY BIOSIMILAR SPACE
  • BIOSIMILARS ARE SET TO CHANGE THE ONCOLOGY TREATMENT LANDSCAPE WITH THE APPROVALS OF COPYCAT VERSIONS OF MABS FOR CANCER TREATMENT.

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area Summary GlobalData’s "The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area", provides an insight-rich overview of the key events and trends that shaped the industry during 2017. Within each of the major therapeutic...

  • Oncology
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.

PD-##/ PD-L## Inhibitors: The First Major Wave of Immuno-Oncology TABLE OF CONTENTS Overview of the current immuno-oncology market Ongoing developments in the PD-##/ PD-L## therapy space Opdivo (nivolumab; Bristol-Myers Squibb/ Ono Pharmaceutical) Keytru

  • Oncology
  • Therapy
  • Japan
  • United States
  • Market Size

Immunomodulators Market Analysis By Product (Immunosuppressant, Immunostimulants, Vaccines, Antibodies), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2014 - 2025 Table of Content Chapter ## Research Methodology & Scope ##. ## Region Wise Market Cal

  • Cancer Immunotherapy
  • Oncology
  • Therapy
  • United States
  • Forecast
  • CHAMPIONS ONCOLOGY
  • 8.2 ONCOLOGY

The humanized mouse models market is projected to grow at a CAGR of 9.9% and humanized rat models market is projected to grow at a CAGR of 8.4%. The humanized mouse models market is projected to reach USD 128.9 million by 2022 from USD 80.3 million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat...

  • Oncology
  • North America
  • United States
  • World
  • Horizon Discovery